DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Income Tax Expense
Income taxes recognized for the period, including current and deferred tax.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026
Income tax expense turns negative
Q1 FY2026 income tax expense was -$7K, compared with $6K a year earlier. Trailing-twelve-month income tax expense was $15K. Over 3 fiscal years it compounded at +0.0% a year.
Context
- Income tax expense increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly income tax expense holds near -$7K or moves back toward the trailing-twelve-month quarterly average of $3.75K.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Tax Expense history
USD · from the income statement
- Latest · FY2025
- 28K USD
- Year-over-year change
- -6.7%
- 4-year CAGR
- +0.0%
| Period | Period end | Income Tax Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28K | -6.7% |
| FY2024 | 2024-12-31 | 30K | -30.2% |
| FY2023 | 2023-12-31 | 43K | +53.6% |
| FY2022 | 2022-12-31 | 28K | +0.0% |
| FY2021 | 2021-12-31 | 28K | — |
Income Tax Expense vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's LTM Mar 2026 income tax expense of $15K is the 3rd highest of the 7 companies compared; the peer median is $0.
- Its year-over-year change of -48.3% is the 2nd highest of 4, against a peer median of -100.0%.
- Over three fiscal years its annual growth of +0.0% compares with a peer median of +23.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.75M | — | — | 0.8% | |
| LTM Jun 2026 | $102K | +50.0% | +69.4% | 2.8% | |
| LTM Mar 2026 | $15K | -48.3% | +0.0% | — | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $0 | — | — | 0.0% |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | -$20.21M | -19151.4% | -22.7% | 2273.8% | |
| Peer median (excluding DMAC) | $0 | -100.0% | +23.3% | 0.8% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 8.77M | 7.84M | 13.11M | 19.06M | 24.61M |
| Selling, General & Admin | 4.88M | 6.16M | 8.16M | 7.62M | 9.78M |
| Operating Expenses | 13.65M | 14M | 21.27M | 26.68M | 34.4M |
| Depreciation & Amortization | 24K | 25K | 30K | 39K | 43K |
| EBITDA | (13.54M) | (13.62M) | (19.31M) | (24.38M) | (32.7M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (13.65M) | (14M) | (21.27M) | (26.68M) | (34.4M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 2.3M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 82K | 353K | 1.93M | 2.27M | 1.66M |
| Income Before Tax | (13.56M) | (13.65M) | (19.34M) | (24.41M) | (32.74M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 28K | 28K | 43K | 30K | 28K |
| Net Income | (13.59M) | (13.68M) | (19.38M) | (24.44M) | (32.77M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.65) | (0.52) | (0.60) | (0.60) | (0.70) |
| EPS (Diluted) | (0.65) | (0.52) | (0.60) | (0.60) | (0.70) |
| Weighted Avg Shares | 20.77M | 26.44M | 32.57M | 40.4M | 46.98M |
| Weighted Avg Shares (Diluted) | 20.77M | 26.44M | 32.57M | 40.4M | 46.98M |
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.